They arent right for everyone, and the side effects can be significant
The researchers analyzed information from the IQVIA Longitudinal Prescription Database on GLP-1 receptor agonist dispensing from 2020 to 2023
Ana Cebrin-Cuenca has the following financial relationships: advisor on scientific boards for Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Eli Lilly and Company, Merck Sharp & Dohme and Novo-Nordisk
[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Yuan S., Larsson S.C
PubMed Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons
2017, Band 22, Nummer 1, S